Mabtech AB and Sai Life Sciences have announced a strategic collaboration to advance immunology research using the EYRA platform at Sai’s Boston facility. The partnership aims to accelerate drug discovery, enhance immunological insights, and strengthen translational research capabilities, reinforcing both companies’ commitment to innovation in life sciences.
Mabtech AB, a global leader in immunoassay development, and Sai Life Sciences, a leading contract research and development organization, have entered into a strategic collaboration to drive innovation in immunology research. The partnership will leverage Mabtech’s EYRA platform at Sai’s Boston site, enabling advanced immunological studies and translational research.
Key Highlights
-
Collaboration Focus: Joint efforts to accelerate immunology research and drug discovery.
-
Technology Platform: Mabtech’s EYRA platform deployed at Sai Boston to enhance immunological assays.
-
Strategic Impact: Strengthens translational research capabilities and supports cutting-edge therapeutic development.
-
Global Reach: Combines Mabtech’s expertise in immunoassays with Sai’s integrated drug discovery services.
-
Innovation Outlook: Partnership expected to deliver deeper insights into immune responses and support next-generation therapies.
This collaboration underscores the growing importance of partnerships between technology innovators and research organizations in advancing biomedical science. By combining Mabtech’s assay technology with Sai’s research infrastructure, the alliance is poised to accelerate breakthroughs in immunology and therapeutic development.
Sources: Company Press Release, Reuters.